On 27 of may the IqHS had organized a scientific meeting in Babylon Rotana Hotel  with the collaboration of Boehringer Ingelheim Pharmaceutical Company about the role of SGLT-2 Inhibitors in the treament of heart failure with reduced ejection fraction HFrEF with special role of Empagliflozin.